Jim Simons Morphic Holding, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $953,450 - $2.66 Million	44,700 Added 70.62%	108,000 $2.47 Million
Q2 2023 Aug 11, 2023	SELL	$34.33 - $62.11 $1,956 - $3,540	-57 Reduced 0.09%	63,300 $3.63 Million
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $1.11 Million - $2.08 Million	-42,743 Reduced 40.29%	63,357 $2.39 Million
Q4 2022 Feb 13, 2023	SELL	$24.14 - $30.37 $818,346 - $1.03 Million	-33,900 Reduced 24.21%	106,100 $2.84 Million
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $1.2 Million - $1.81 Million	54,200 Added 63.17%	140,000 $3.96 Million

Q2 2022 Aug 12, 2022	BUY	$19.74 - $43.01 $1.69 Million - $3.69 Million	85,800 New	85,800 $1.86 Million
Q1 2021 May 13, 2021	SELL	$29.77 - $84.85 $1.22 Million - $3.47 Million	-40,900 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$25.66 - $34.55 $1.05 Million - $1.41 Million	40,900 New	40,900 $1.37 Million

142

37.9M

13.5K

190K

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $1.31B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.